Researchers at Korea's Daegu Gyeongbuk Institute of Science & Technology have created a nuclear battery that could turn ...
Preclinical data demonstrates that SPY003 is highly potent and has potential forquarterly or biannual dosing, suggesting opportunity for improved efficacy ...
6d
News-Medical.Net on MSNHow your diet and probiotics can improve vaccine effectivenessResearchers uncover how probiotics and diet shape the gut microbiome to boost vaccine efficacy, offering new avenues for ...
3d
Zacks.com on MSNWave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar?Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near ...
Finally fed up with the detective lark, Holmes retires to the village of Fulworth to start a new life as a beekeeper. He's eventually joined by Dr Watson, who Holmes wants to help "rest and recuperate ...
1d
IFLScience on MSNThe Tetris Effect Is More Than A Gaming Quirk, It’s Changing How We See MemoryYou can often hear people saying that a game, an album, a movie, or a TV series have altered their brain chemistry.
5d
24/7 Wall St. on MSNA Simple 15-Minute 401(k) Checkup Can Potentially Add $75,000 to Your Nest EggOnce people set up their retirement plan contributions at work, they are often put on the back burner. Out of sight, out of ...
3d
ZME Science on MSNThis Tiny Nuclear Battery Could Last for Thousands of Years Without ChargingBecause it decays slowly — with a half-life of 5,730 years — a radiocarbon battery could theoretically last millennia. That’s ...
Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...
4d
Interesting Engineering on MSNNew radiocarbon-powered nuclear battery can run for millennia without rechargingScientists have developed a prototype nuclear battery using radiocarbon that could power small devices for decades without ...
In April 2024, Entera announced that the Journal of Bone and Mineral Research (JBMR) published EB613 placebo controlled Phase 2 Trial results, highlighting its dual mechanism of action and rapid ...
Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient randomized and enrollment continues as plannedACTengine® IMA203 T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results